郑州近视可以自己怎么矫正(郑州近视眼手术有年龄限制) (今日更新中)

KAMPALA, May 14 (Xinhua) -- The deadly Ebola hemorrhagic fever has broken out in Uganda, killing one person and leaving over 30 others being monitored by health officials, ministry of health announced here on Saturday.The epicenter of the outbreak is in the central Ugandan district of Luwero located about 50 km north of the capital Kampala.According to Anthony Mbonye, head of the community health department at the ministry of health, a 12 year old girl in Zirombwe Sub-county developed symptoms of Ebola and when she was admitted at a military hospital in the district, laboratory test confirmed that it was Ebola.The Ebola virus is highly contagious and causes a range of symptoms including fever, vomiting, diarrhea, generalized pain or malaise and in many cases internal and external bleeding.The girl died on May 6 and about 30 people who she got contact with are being asked to not get into contact with the public as health officials monitor them for about 21 days.The 30 people have not yet developed the symptoms but if they do, they will be isolated from the public.Mbonye said that preliminary investigations have showed that this Ebola virus is similar to the one that broke out in Sudan, thus named Sudan Ebola.The epicenter of the outbreak is also located along the high way to southern Sudan.This viral subtype has a human case fatality rate of 60 percent meaning that it will kill 60 percent of the infected people.The other subtype is the Congo Ebola which also attacked Uganda in 2007. This one has a human case fatality rate of over 80 percent.The 2007 outbreak which occurred in the western district of Bundibugyo bordering eastern Democratic Republic of Congo claimed 37 lives out of the 148 infected.Mbonye said that there also ongoing investigations to find out whether the index case got into contact with moneys or bats, the known reservoirs of the Ebola virus.Following the outbreak, government has reactivated the National Ebola Task Force (NETF) to coordinate the fight against the disease at the national level.District task forces are also in the process of being formed according to Mbonye, who is the chairperson of the NETF.

CANBERRA, May 26 (Xinhua) -- Australian Health Minister Nicola Roxon on Thursday night said she will not be frightened off by the tobacco industry's attempt to lobby Malaysia to oppose the Australian government's proposal for plain packaging of cigarettes.According to ABC News, big tobacco companies have appointed a former United States ambassador to the World Trade Organization ( WTO), Peter Allgeier, to help them fight the Australian federal government's plain packaging plan, which is due to come into effect this year.An email sent to a Malaysian official and obtained by ABC News showed that Allgeier had a meeting with Malaysia's trade minister before, and he has been lobbying a Malaysian administrator to put pressure on Australia over plain packaging.Allgeier's email also stated that "members of the U.S. congress also have written to the Australian Government outlining concerns about the implications of plain packaging for the integrity of Australia's trade commitments."However, Roxon, who said she has not been approached by Malaysia on the issue, said Allgeier's appointment demonstrated just how far big tobacco is prepared to take its fight."But we won't be frightened off because big tobacco is hiring lobbyists or looking at ways to influence the action we're taking, " she told ABC television on Thursday night.The tobacco industry has already spent millions fighting plain packaging, and last year gave 5.2 million U.S. dollars to the Alliance of Australian Retailers (AAR) to fund an advertising campaign against the plan.If the cigarettes law is enforced, Australia will become the first country in the world to ban logos and brand names from cigarette packaging. Health warnings and the kind of graphic pictures will make up the majority of the packaging, while the rest of the packets will be plain olive green.

WASHINGTON, April 25 (Xinhua) -- A class of drugs that shows promise in breast and ovarian cancers with BRCA gene mutations could potentially benefit colorectal cancer patients with a different genetic mutation, a new study from the University of Michigan Comprehensive Cancer Center finds.Working in cell lines from colorectal cancer patients, researchers found that the class of drugs called PARP inhibitors worked against tumors with mutations in the MRE11 gene.About 15 percent of all colorectal cancers have what's called microsatellite instability, a type of error in the DNA. About 82 percent of those tumors have the MRE11 gene mutation."This is a potential broader application for PARP inhibitors, beyond breast and ovarian cancer. This is a class of drug that's already shown safety in early clinical trials and now might benefit some colorectal cancer patients as well," says lead study author Eduardo Vilar-Sanchez, a hematology/oncology fellow at the university, in a statement.The study, which was published Monday in Cancer Research, also found that PARP inhibitors are even more effective when both copies of MRE11 were mutated. Each person carries two copies of each gene, which means mutations can occur in either one or both copies. The researchers suggest that PARP inhibitors could be targeted specifically to colorectal cancer patients who have two copies of the mutated gene.Researchers are planning a phase I clinical trial to look at using PARP inhibitors in colorectal cancer patients with two mutated copies of MRE11. Future trials are being considered using PARP inhibitors to prevent colorectal cancer and other cancers in people with Lynch syndrome whose tumors have this mutation.Microsatellite instability is also seen in prostate cancer and endometrial cancer, suggesting potential for PARP inhibitors to play a role in additional types of cancer as well, Vilar-Sanchez says, adding that more research is needed in these areas.

BEIJING, May 25 (Xinhua) -- A researcher with the Chinese Academy of Agricultural Sciences (CAAS) said Wednesday that plant hormones, if used properly, are not a risk to human health."Irregular use of plant growth substances may cause plants to grow excessively fast or affect the taste, but will not cause harm to human health," Ye Zhihua said in an interview with Xinhua.His remarks come after media reports in China about "exploding watermelons," caused by the excessive use of phytohormone, have aroused public concern over the safety of hormones that stimulate plant growth.Ye said plant hormones used to promote growth have the same or similar effects as natural plant hormones, and fruit and vegetables sold at the market carried limited residue of the hormones.More than 100 types of plant hormones, such as ethephon and gibberellin acid, are used in agriculture and forestry sectors around the world, Ye said, adding 38 types of plant hormones have been registered in China.For example, seven plant hormones including thidiazuron and nucleotide are approved for use on cucumbers in China. The purpose is to stimulate the growth of female flowers and increase fruit yields, Ye said.Ye added that China places plant hormones in the category of pesticides control, which means the hormones are subject to strict management from production to utilization.

SAN FRANCISCO, May 4 (Xinhua) -- Intel Corp. on Wednesday announced that it will mass-manufacture chips using new transistors featuring a three-dimensional (3-D) structure, calling it a technical breakthrough in microprocessors.The 3-D transistor, called Tri-Gate, represents a fundamental departure from the two-dimensional planar transistor structure that has powered computers, mobile phones and other modern electronics, Intel said."Intel's scientists and engineers have once again reinvented the transistor, this time utilizing the third dimension," Paul Otellini, Intel's chief executive officer, said in a statement.Intel on Wednesday also demonstrated a 22-nanometer (nm) microprocessor, codenamed "Ivy Bridge," which will be the first high-volume chips to use the new 3-D transistors.Ivy Bridge is scheduled for high-volume production readiness by the end of this year, the company said.According to Intel, the 3-D transistors enable chips to operate at lower voltage with lower leakage compared to previous transistors, providing up to 37 percent performance increase at low voltage versus the company's 32nm planar transistors.The gain means that the new 3-D transistors are ideal for use in small handheld devices, which operate using less energy to " switch" back and forth, Intel noted.

来源：资阳报